Lanean...

Immunotherapy for head and neck cancer: Recent advances and future directions

Three randomized phase III trials have now conclusively proven that exposure to a PD-1 inhibitor prolongs survival in recurrent/metastatic (R/M) HNSCC, and it is clear that such agents should be used in the management of all patients who do not have contraindications to their use. Two of these phase...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oral Oncol
Egile Nagusiak: Cramer, John D., Burtness, Barbara, Ferris, Robert L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7749717/
https://ncbi.nlm.nih.gov/pubmed/31683169
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2019.104460
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!